HIV
Conditions
Keywords
HIV
Brief summary
This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects currently attending for HIV care at St. Mary's Hospital, London will be eligible.
Detailed description
The study will describe the steady state pharmacokinetic parameters and short term safety of maraviroc/darunavir/ritonavir dosed at 150/800/100 mg once daily with and without tenofovir/emtricitabine 245/200 mg once daily in HIV-1 infected subjects. Fifteen HIV-1 infected subjects will be recruited. Eligible subjects will currently be receiving antiretroviral therapy comprising: * tenofovir/emtricitabine 245/200 mg daily plus * darunavir/ritonavir 800/100 mg daily On day 1, subjects will modify their current antiretroviral therapy to the following: * tenofovir/emtricitabine 245/200 mg daily plus * darunavir/ritonavir 800/100 mg daily plus * maraviroc 150 mg daily On day 10 subjects will undergo an intensive pharmacokinetic visit. On day 11, subjects will modify their current antiretroviral therapy to the following: * darunavir/ritonavir 800/100 mg daily plus * maraviroc 150 mg daily (i.e. tenofovir/emtricitabine will be discontinued) On day 20 subjects will undergo an intensive pharmacokinetic visit. Following completion of this study phase, subjects will recommence their usual antiretroviral treatment regimen and attend for a study follow up visit.
Interventions
DRUGMaraviroc
Maraviroc 150 mg daily
DRUGTruvada
daily until 10. day then stop
DRUGDarunavir
daily until 10. day then stop
Sponsors
Imperial College London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* HIV-1 infected males or females * signed informed consent * plasma HIV RNA \< 50 copies/mL at screening and on at least one other occasion over the last 3 months * currently receiving an antiretroviral regimen comprising of: tenofovir 245 mg daily,emtricitabine 200 mg daily, darunavir 800 mg daily and ritonavir 100 mg daily * no previous protease inhibitor resistance documented on HIV-1 genotypic resistance testing if an HIV resistance test available * Between 18 to 65 years of age, inclusive * subjects in good health upon medical history, physical exam, and laboratory testing * BMI above or equal to 18 and below 32 * Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening until 8 weeks after completion of the study: * barrier contraceptives (condom OR diaphragm PLUS spermicide) or oral, implant or injectable hormonal contraceptive PLUS a barrier contraceptive or * IUD /IUS PLUS a barrier contraceptive * Female subjects of childbearing potential must have a negative urine pregnancy test. * Male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study. * Have no serologic evidence of active HBV infection evidenced by negative hepatitis B surface antigen and no serologic evidence of hepatitis C virus infection evidenced by a negative HCV antibody at screening. * Have screening laboratory results (haematology and chemistry that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the Investigator to have no clinical significance * CCR5 tropic HIV virus based on a genotypic tropism assay from either a stored plasma sample where available or fresh plasma
Exclusion criteria
* current alcohol abuse or drug dependence * positive urine drug of abuse screening * pregnancy * active opportunistic infection or significant co-morbidities * current disallowed concomitant medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day | 10 day, 20 days | On day 10 of the study the maximum concentractions of maraviroc will be measured . On day 20 of the study the maximum plasma concentractions maraviroc will be measured . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Changes in Haematology and Biochemistry Laboratory Tests | 35 days | Haematology and biochemistry laboratory tests such as full blood count, elelectrolytes and lipids will be measured to assess for changes. |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Truvada, Darunavir/r and Maraviroc Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
Maraviroc: Maraviroc 150 mg daily | 11 |
| Total | 11 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| With Tenofovir/Emtricitabine (10 Days) | Physician Decision | 1 |
| With Tenofovir/Emtricitabine (10 Days) | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Truvada, Darunavir/r and Maraviroc |
|---|---|
| Age, Continuous | 48 years STANDARD_DEVIATION 8.8 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 8 Participants |
| Region of Enrollment United Kingdom | 11 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 11 |
| other Total, other adverse events | 0 / 11 |
| serious Total, serious adverse events | 0 / 11 |
Outcome results
Primary
The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day
On day 10 of the study the maximum concentractions of maraviroc will be measured . On day 20 of the study the maximum plasma concentractions maraviroc will be measured .
Time frame: 10 day, 20 days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Truvada, Darunavir/r and Maraviroc | The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day | 0.99 ratio |
Secondary
Number of Participants With Changes in Haematology and Biochemistry Laboratory Tests
Haematology and biochemistry laboratory tests such as full blood count, elelectrolytes and lipids will be measured to assess for changes.
Time frame: 35 days
Population: No data reported
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Truvada, Darunavir/r and Maraviroc | Number of Participants With Changes in Haematology and Biochemistry Laboratory Tests | 0 Participants |